The OCU410ST Phase 2/3 pivotal confirmatory trial represents Ocugen’s second late-stage clinical program. Ocugen plans to submit the BLA for OCU410ST mid-2027 in alignment with its strategic goal of ...
An Australian study 1 reported that directional optical coherence tomography (OCT) images showed that Parkinson’s disease (PD) is associated with a thicker photoreceptor nuclear ...
The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results